F ate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in the company's Phase 1 Autoimmunity study for its CAR T-cell therapy ...

YTD Price Performance: 0.56% Average Trading Volume: 2,961,505 Technical Sentiment Consensus Rating: Buy Current Market Cap: $205M For a thorough assessment of FATE stock, go to TipRanks’ Stock ...

Barclays analyst Peter Lawson assigned a Buy rating to Fate Therapeutics (FATE – Research Report) today and set a price target of $10.00. The ...